3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Breast
1
Conditions
Breast Neoplasms
14
Carcinoma, Non-Small-Cell Lung
8
Precursor Cell Lymphoblastic Leukemia-Lymphoma
5
Neoplasms
4
Melanoma
4
Lung Neoplasms
4
Leukemia, Myelomonocytic, Chronic
4
Leukemia, Myeloid, Acute
4
Breast Diseases
4
Thoracic Neoplasms
3
Respiratory Tract Neoplasms
3
Lung Diseases
3
Bronchial Neoplasms
3
Uveal Melanoma
2
Sezary Syndrome
2
Rectal Neoplasms
2
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
Pinealoma
2
Pancreatic Neoplasms
2
Neoplasms, Glandular and Epithelial
2
Neoplasms by Histologic Type
2
Myeloproliferative Disorders
2
Myelodysplastic Syndromes
2
Mycosis Fungoides
2
Lymphoma, T-Cell, Cutaneous
2
Lymphoma, Non-Hodgkin
2
Lymphoma, Mantle-Cell
2
Lymphoma, Large-Cell, Immunoblastic
2
Lymphoma, Large-Cell, Anaplastic
2
Lymphoma, Large B-Cell, Diffuse
2
Interventions
Gefitinib
3
Erlotinib Hydrochloride
3
sotorasib
1
pralsetinib
1
osimertinib
1
ficlatuzumab
1
exemestane
1
entinostat
1
durvalumab
1
cobimetinib
1
camrelizumab
1
Tyrosine Kinase Inhibitors
1
Radiosurgery
1
Prednisone
1
Pemetrexed
1
Leuprolide
1
Dasatinib
1
Carboplatin
1
Afatinib
1
AZD3759
1
4-((1,4,8,11-tetraazacyclotetradec-1-yl)methyl)benzoic acid
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Respiratory Tract Diseases
×
entinostat
×
Clear all
NCT01594398
2021-11-19
ENCORE110
Syndax Pharmaceuticals
Phase 1
Completed
14 enrolled